Abstract

COMPARATIVE STUDIES OF TELMISARTAN MARKETED TABLETS

Nikitha Chakala, Sugandhi Puvvadi, S. Varalaxmi* and J. Neha Venkata Durga

ABSTRACT

Systemic arterial hypertension is the leading risk factor for global morbidity and mortality, linked to increased cardiovascular disease risk. Although treatment lowers disease burden, less than half of individuals are aware of their condition, and many are not treated effectively. hypertension patients. Morning treatment requires a longacting hypertension drug with a high lipophilicity and 24-hour elimination half-life, such as Telmisartan. There are large number of different brands of marketed Telmisartan tablets. This research is intended to provide an information on the tablets available for patientcare by performing evaluation studies on marketed Telmisartan tablets according to official standards.

Keywords: Hypertension, angiotensin II, Telmisartan.